Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases
Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany, .Clinical Rheumatology (Impact Factor: 1.77). 11/2013; 33(1). DOI: 10.1007/s10067-013-2435-8
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.